Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in High Risk Relapsed Multiple Myeloma: Multicenter Real-World Experience

被引：0
|
作者：
Magee, Gray [1 ,2 ]
Mansour, Razan [2 ,3 ]
Chang, Mark [1 ,2 ]
Atrash, Shebli [2 ,4 ]
Ahmed, Nausheen [2 ,5 ]
Mushtaq, Muhammad Umair [2 ,6 ]
Ouchveridze, Evguenia [2 ,7 ]
Abdallah, Al-Ola [2 ,5 ]
Paul, Barry [2 ,4 ]
Green, Kimberly M. [2 ,8 ]
Davis, James A. [2 ,8 ]
Hashmi, Hamza [2 ,9 ]
机构：
[1] Atrium Hlth, Levine Canc, Charlotte, NC 28207 USA
[2] US Myeloma Innovat Res Collaborat USMIRC, Kansas City, KS USA
[3] Univ Kansas Med Ctr, Internal Med, Kansas City, KS USA
[4] Wake Forest Univ, Bowman Gray Sch Med, Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[5] Univ Kansas Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS USA
[6] Univ Kansas Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Overland Pk, KS USA
[7] Univ Kansas Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Westwood, KS USA
[8] Med Univ South Carolina, Div Hematol Oncol, Charleston, SC USA
[9] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-208085
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7034 / 7035
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Daratumumab-Naive Relapsed Multiple Myeloma: Multicenter Real-World Experience
    Mansour, Razan
    Davis, James A.
    Minchak, Megan
    Atallah, Rawan
    Saif, Md Saiful Islam
    Logan, Emerson
    Tabak, Carine
    Rashid, Aliya
    Dima, Danai
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2023, 142
  • [2] Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma
    Dima, Danai
    Mansour, Razan
    Davis, James A.
    Minchak, Megan
    Goel, Utkarsh
    Atallah, Rawan
    Logan, Emerson
    Tabak, Carine
    Rashid, Aliya
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Hashmi, Hamza
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (06) : 975 - 983
  • [3] Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naive Relapsed Multiple Myeloma
    Afrough, Aimaz
    Atrash, Shebli
    Paul, Barry
    Ouchveridze, Evguenia
    Ahmed, Nausheen
    Mahmoudjafari, Zahra
    Bashir, Anam
    Alkharabsheh, Omar
    Hashmi, Hamza
    Abdallah, Al-Ola
    CANCERS, 2023, 15 (19)
  • [4] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    BLOOD, 2017, 130 (08) : 974 - 981
  • [5] phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Sperling, Adam
    Bianchi, Giada
    Munshi, Nikhil
    O'Donnell, Elizabeth
    Branagan, Andrew
    Avigan, David
    Liegel, Jessica
    Harrington, Cynthia
    Agyemang, Emerentia
    Lively, Kathleen
    Packer, Lisette
    Han, Samuel
    Minsky, Cole
    Riadi, Manal
    Mcvey, Cailin
    Donnelly, Kaleigh
    Smith, Caitlin
    Katzeff, Mackenna
    Goguen, Amy
    Horick, Nora
    Richardson, Paul
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S220 - S221
  • [6] Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
    Derman, Benjamin A.
    Zonder, Jeffrey
    Reece, Donna
    Cole, Craig
    Berdeja, Jesus
    Stefka, Andrew T.
    Major, Ajay
    Kin, Andrew
    Griffith, Kent
    Jasielec, Jagoda
    Jakubowiak, Andrzej J.
    BLOOD ADVANCES, 2023, 7 (19) : 5703 - 5712
  • [7] Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma
    Hussain, M. Junaid
    Robinson, Myra M.
    Hamadeh, Issam
    Arnall, Justin
    Bhutani, Manisha
    Atrash, Shebli
    Friend, Reed
    Pineda-Roman, Mauricio
    Symanowski, James T.
    Usmani, Saad Z.
    Voorhees, Peter M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (01) : 140 - 144
  • [8] Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients
    Fu, Chengcheng
    You, Hongying
    Jin, Song
    Wang, Panfeng
    Yan, Lingzhi
    Zhang, Liying
    Lu, Tingting
    Gao, Xiao
    Jiang, Lei
    Qiu, Hongchun
    Shang, Jingjing
    Zhai, Yingying
    Yao, Weiqin
    Yan, Shuang
    Yan, Zhi
    Wu, Depei
    BLOOD, 2024, 144 : 6992 - 6993
  • [9] Carfilzomib, Pomalidomide, Dexamethasone with and without Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multi-Center, Prospective Real World Study in China
    Zhang, Fujing
    Wang, Wei
    Wang, Hua
    Wang, Wei
    Liu, Aijun
    Tian, Weiwei
    Qin, Xiaoqi
    Xia, Zhongjun
    Zhuang, Junling
    BLOOD, 2024, 144 : 6985 - 6986
  • [10] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Pineiro, Luis
    Jakubowiak, Andrzej
    de Boer, Carla
    Wang, Jianping
    Clemens, Pamela L.
    Ukropec, Jon
    Schecter, Jordan
    Lonial, Sagar
    Moreau, Philippe
    BLOOD, 2019, 134 (05) : 421 - 431
12345